Barbara Burtness MD
Anthony N. Brady Professor of Medicine; Chief Translational Research Officer; Associate Director, Translational Science; Division Chief, Head and Neck/Sarcoma Oncology; Co-Leader, Developmental Therapeutics Program; Director, Yale Head and Neck SPORE, Yale Cancer Center, Yale School of Medicine, New Haven, ConnecticutDr. Barbara Burtness is Anthony N. Brady Professor of Medicine at the Yale University School of Medicine. She is founding director of the Yale Head and Neck SPORE, co-leader of the Developmental Therapeutics Program, and director of the Head and Neck Clinical Research Program at Yale Cancer Center. Dr. Burtness graduated with an MD from SUNY at Stonybrook. She completed internship and residency at Yale-New Haven Hospital and fellowship training in oncology at Memorial Sloan Kettering Cancer Center.
Dr. Burtness' research focuses on clinical trials of immunotherapy and translational studies of resistance to immunotherapy and EGFR inhibition, and synthetic lethal approaches for HPV negative head and neck cancer. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multi-center trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers, and co-leads the Stand Up to Cancer Head and Neck Cancer Team. She has conducted numerous phase I–III investigator-initiated trials.
Dr. Burtness co-edits the text Molecular Determinants of Head and Neck Cancer. Her research has been published in numerous peer-reviewed journals, including the Lancet, Journal of Clinical Oncology, Lancet Oncology, and Clinical Cancer Research.
Disclosures
Honoraria/Consulting/Data Safety Monitoring Boards:
AbbVie, ALX Oncology, Astra Zeneca, Coherus, Cue Biopharma, Eisai, Glaxo Smith Kline, IMS Consulting, IO Biotech, Kura, Merck KgA, Merck, Merus, Orphagen, Vaccinex, Slingshot, Surface
Recent Contributions to PracticeUpdate:
- Phase III KEYNOTE-412: Pembrolizumab With Chemoradiation Therapy vs Placebo Plus CRT for Locally Advanced HNSCC
- Phase VI KEYNOTE-B10: Pembrolizumab Plus Carboplatin Plus Paclitaxel as First-line Therapy in R/M HNSCC
- ESMO 2022: Recommendations From Dr. Barbara Burtness for Head and Neck Cancer
- Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer Unsuitable for Cisplatin-Based Chemoradiation
- Weekly vs Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Pembrolizumab and Cabozantinib for Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
- Transoral Surgery Followed by Pathology-Based Adjuvant Treatment in HPV-Associated Oropharynx Cancer
- ASCO 2022: Abstract Recommendations From Dr. Barbara Burtness for Head and Neck Cancer
- 2021 Top Story in Head and Neck Cancer: Change in Standard of Care for EBV-Related Nasopharyngeal Cancer
- Elective Neck Dissection vs Observation in Patients With Head and Neck Cutaneous Squamous Cell Carcinoma